PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer

CONCLUSIONS: With PSMA-11-PET we are able to select patients with oligometastatic recurrent prostate cancer suitable for SABR in an earlier disease stage at lower PSA levels. PSMA-11-PET guided SABR resulted in a significant longer response duration and ADT-free survival compared with choline-PET and can therefore prevent or delay ADT related side effects.PMID:34278008 | PMC:PMC8261473 | DOI:10.1016/j.ctro.2021.06.004

Source: Clinical Prostate Cancer - July 19, 2021 Category: Cancer & Oncology Authors: Charlotte L Deijen Gerbert L Vrijenhoek Eva E Schaake Wouter V Vogel Luc M F Moonen Floris J Pos Henk G van der Poel Gerben R Borst Source Type: research